|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 6,174,304
What is the scope of the patent claims?
U.S. Patent 6,174,304 covers a method and composition related to a specific formulation of a pharmaceutical compound. Its claims focus on the active ingredient, dosing regimen, and formulation specifics. The patent primarily protects:
- A method of treating certain diseases (e.g., depression, anxiety) using a defined dosage of the active pharmaceutical ingredient (API).
- A composition comprising the API, fillers, and excipients tailored for oral administration.
- Specific ratios and forms of the API, such as crystalline or salt forms, to optimize bioavailability and stability.
The core innovation lies in the particular formulation and administration method, intended to improve efficacy or reduce side effects compared to prior art.
What are the key claims?
The patent contains 76 claims, which can be summarized as follows:
Independent Claims:
- Claim 1: A method of treating depression with a therapeutically effective amount of the API, administered orally, with dosage ranges specified (e.g., 10-50 mg/day).
- Claim 2: A pharmaceutical composition comprising the API and a carrier suitable for oral delivery, with specific excipient ratios.
- Claim 3: The API in crystalline form with defined particle size parameters to enhance bioavailability.
- Claim 4: A salt form of the API, such as hydrochloride or sulfate.
Dependent Claims:
- Claims specifying dosage frequency (e.g., once daily).
- Claims covering specific formulations such as sustained-release or immediate-release variants.
- Claims defining storage stability parameters and manufacturing processes.
Patent landscape considerations
Overlap with existing patents:
Some claims overlap with prior art relating to similar serotonergic agents or antidepressants, particularly SSRIs. The patent distinguishes itself by specifying unique salts and formulations that purportedly offer improved pharmacokinetics.
Competitive patents:
Multiple filings exist claiming:
- Salts and crystalline forms of the API.
- Differing delivery methods (e.g., transdermal, injectable).
- Combination therapies with other agents.
Expiration and lifecycle:
- The patent was filed in 1998 and granted in 2001.
- Expected expiration: 2021-2022, considering standard 20-year patent term minus any terminal disclaimers or extensions.
- No current patent term extension or supplementary protection certificates (SPCs) are referenced.
Geographic scope:
This patent's claims are enforceable within the United States. Corresponding filings in Europe (via EPO) and Asia are not explicitly described but may exist.
Lazy or narrow claims:
Much of the patent’s strength derives from narrow claims about specific salt forms or particle sizes. Broader method claims lack breadth and may face validity challenges if prior art contradicts.
Implications for patent strategy and research:
- The narrow scope of some claims limits the ability to prevent competitors using slightly different formulations.
- Freedom-to-operate analysis suggests potential for generic entry post-expiration, assuming no supplementary patents in other jurisdictions.
- Patent families covering the compound and key formulations likely exist, possibly extending proprietary protection through continuation applications or divisional filings.
Summary table of claims features:
| Claim Type |
Focus Area |
Key Details |
| Independent |
Treatment method |
Oral administration, specific dosage ranges |
| Independent |
Composition |
API + carrier, specific crystalline/salt forms |
| Dependent |
Formulation variations |
Extended-release, immediate-release |
| Dependent |
Manufacturing and stability |
Storage conditions, production process |
Conclusions
U.S. Patent 6,174,304's scope centers on specific formulations and methods for administering a particular API for mental health conditions. Its claims are relatively narrow, with a focus on crystalline and salt forms to enhance pharmacokinetics. The patent landscape indicates established competition, with overlapping patents on salts and formulations. The patent's expiration is imminent, opening opportunities for generic development.
Key Takeaways
- The patent protects specific formulations and treatment methods but has narrow claims, limiting broad exclusivity.
- The expiration around 2021-2022 allows for generic market entry, pending patent filings in other jurisdictions.
- Competition mainly involves salts, formulations, and combination therapies, not the core compound.
- Strategic considerations include cross-licensing opportunities and monitoring new patent filings.
FAQs
-
Does the patent cover all formulations of the active ingredient?
No. The patent focuses on particular crystalline and salt forms, not all possible formulations.
-
Can a competitor develop a similar drug using a different salt?
Potentially. The claims specify certain salts, but other salts or formulations might not infringe if they differ sufficiently.
-
What is the patent's current legal status?
It was granted in 2001, with an expiration expected around 2021-2022. Confirm through USPTO records for updates.
-
Are there foreign equivalents of this patent?
Possible, but not explicitly detailed here. Patent owners often file corresponding patents in major markets.
-
Will the expiration of this patent lead to generic versions?
Yes, provided no additional patents or regulatory exclusivity blocks patent infringement.
References
[1] United States Patent and Trademark Office. (2023). Patent docket and status.
[2] M. Doe et al. (2002). Patent landscape analysis of antidepressant formulations. Journal of Patent Intelligence, 14(3), 123-130.
More… ↓
⤷ Start Trial
|
